Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
| Previous Close | 1.5320 |
| Open | 1.5200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.5320 - 1.5320 |
| 52 Week Range | 1.5150 - 2.9150 |
| Volume | |
| Avg. Volume | 7,114 |
| Market Cap | 7.487B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 12.77 |
| EPS (TTM) | 0.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.06 (3.83%) |
| Ex-Dividend Date | Jul 31, 2023 |
| 1y Target Est | N/A |
- PR Newswire
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
- Reuters
India's Gland Pharma posts 41% jump in quarterly revenue on Cenexi acquisition
Indian generic injectables maker Gland Pharma Ltd reported a 41% jump in first-quarter revenue on Monday, aided by its acquisition of French pharmaceutical group Cenexi. The Hyderabad-based company, which draws the bulk of its revenue from the United States, Europe, Canada, Australia and New Zealand, said revenue jumped to 12.09 billion Indian rupees ($146.13 million) from 8.57 billion rupees. The company said 37% of the total revenue came from its acquisition of Cenexi in January.
